Key result
Phosphodiesterase-5 inhibitors significantly improved exercise capacity and lowered pulmonary pressures in patients with pulmonary arterial hypertension, and were well tolerated.
Why the study?
Do phosphodiesterase-5 (PDE-5) inhibitors improve efficacy outcomes and demonstrate safety in patients with pulmonary arterial hypertension?
Population
Patients with pulmonary arterial hypertension (PAH) included in 10 randomized clinical studies
Design
Systematic_review
Authors
Loading...
PDE-5 inhibitors remain a viable PAH option; leaves open optimal agent selection and long-term comparative effectiveness.
Systematic Review
Do phosphodiesterase-5 (PDE-5) inhibitors improve efficacy outcomes and demonstrate safety in patients with pulmonary arterial hypertension?
PDE-5 inhibitors, particularly sildenafil, are an effective and well-tolerated therapeutic option for improving exercise capacity and lowering pulmonary pressures in patients with pulmonary arterial hypertension.
Feldman et al. (2010) conducted a systematic review in Pulmonary arterial hypertension (PAH). Phosphodiesterase-5 (PDE-5) inhibitors was evaluated. Phosphodiesterase-5 inhibitors significantly improved exercise capacity and lowered pulmonary pressures in patients with pulmonary arterial hypertension, and were well tolerated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: